论文部分内容阅读
目的探讨阿托伐他汀对急性脑梗死(ACI)患者血清超敏C-反应蛋白(hs-CRP)水平的影响,以及hs-CRP水平与ACI病情程度的关系。方法将2012年7月至2013年1月神经内科住院的64例ACI患者按照有无接受阿托伐他汀治疗随机分为阿托伐他汀组32例和常规治疗组32例,另选30例健康体检者为正常对照组。比较ACI组和正常对照组血清hs-CRP水平,并比较不同病情程度的ACI患者hs-CRP水平,观察阿托伐他汀组和常规治疗组治疗前后血清hs-CRP水平及神经功能缺损程度评分的变化。结果 ACI组血清hs-CRP水平明显高于正常对照组(P<0.05);神经功能缺损程度越重,血清hs-CRP含量越高(P<0.05);治疗1个月后,阿托伐他汀组和常规治疗组血清hs-CRP水平和神经功能缺损评分均降低,阿托伐他汀组降低更明显(P均<0.05)。结论 ACI的发生和病情程度与血清hs-CRP水平有关,阿托伐他汀能降低ACI患者血清hs-CRP水平,改善神经功能,可作为ACI发生及其严重程度、预后的预测因子。
Objective To investigate the effect of atorvastatin on serum hs-CRP level in patients with acute cerebral infarction (ACI) and the relationship between hs-CRP level and severity of ACI. Methods 64 patients with ACI hospitalized from July 2012 to January 2013 in neurology department were randomly divided into atorvastatin group (32 cases) and conventional treatment group (32 cases) according to the treatment of atorvastatin. Another 30 cases were selected as healthy Physical examination for the normal control group. The levels of hs-CRP in ACI group and normal control group were compared. The hs-CRP levels in ACI patients with different severity were compared. The levels of serum hs-CRP and neurological deficit score were observed before and after treatment in atorvastatin group and conventional treatment group Variety. Results Serum hs-CRP level in ACI group was significantly higher than that in normal control group (P <0.05). The severity of neurological deficit was higher and serum hs-CRP level was higher (P <0.05). After 1 month of treatment, atorvastatin Serum levels of hs-CRP and neurological deficit scores were decreased in the group and the conventional treatment group, and decreased more significantly in the atorvastatin group (all P <0.05). Conclusions The occurrence and severity of ACI are related to the level of serum hs-CRP. Atorvastatin can reduce the level of serum hs-CRP and improve the neurological function in ACI patients, which may be used as predictors of the occurrence, severity and prognosis of ACI.